Stryka Pro1
Alternative Names: Stryka-Pro1Latest Information Update: 25 Sep 2020
At a glance
- Originator University of Nevada Reno
- Developer Strykagen
- Class Recombinant proteins
- Mechanism of Action Integrin stimulants; Utrophin activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy; Muscular dystrophies
Most Recent Events
- 24 Sep 2020 Stryka Pro1 is available for licensing as of 24 Sep 2020. www.strykagen.com
- 24 Sep 2020 Strykagen plans phase I development in Duchenne muscular dystrophy and Muscular dystrophies (Strykagen website, September 2020)